COVID-19 preclinical drug development database

Dose selection of therapeutics targeting COVID-19 using the hollow fibre infection model

University of Liverpool

Added 15/05/2020 | Updated 04/06/2020

Project Details

Type of project

  • Tier 2: testing existing molecules
  • Tier 3: discovering and categorising new molecules
  • Supporting technologies, models and assays

Therapeutic target

  • Direct acting antiviral

Type of supporting technology

  • In vitro hollow fibre infection model system for SARS-Cov-2

Phase of project

  • PK/PD testing and toxicology

Modality (if can be disclosed)*

  • Small molecule

Molecular/cellular target (if known or can be disclosed)*

  • Not known
  • Not disclosed

Partner institutions/organisations

  • Liverpool School of Tropical Medicine

Key contact

Name: Shampa Das

Email Address: shampa.das@liverpool.ac.uk

Phone Number:

Key Collaborators:

Anticipated timeframe of future outputs

12+ months

Further Details

Abstract or additional information (if available)*

Novel approaches are urgently required to establish effective clinical regimens for SARSCov- 2. Pharmacokinetics-pharmacodynamics (PK-PD) provides the tools to ensure the optimal dosing required is used. Hollow fibre infection models (HFIM) are widely used in antimicrobial drug development. Currently, there are no HFIM models of SARS-CoV-2 and no way to quickly identify regimens for new or repurposed antivirals.

Published outputs (if available)*